NASDAQ:ACAD

ACADIA Pharmaceuticals Stock Forecast, Price & News

$25.17

-0.86 (-3.30 %)

(As of 06/21/2021 03:34 PM ET)

Add

Compare

Today's Range

$25.05

▼

$25.91

50-Day Range

$19.40

▼

$27.42

52-Week Range

$19.20

▼

$58.72

Volume51,588 shs

Average Volume2.01 million shs

Market Capitalization$4.03 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.74

30 days | 90 days | 365 days | Advanced Chart

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

FINAL DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
June 21, 2021 | finance.yahoo.com

CLASS ACTION UPDATE for ACAD, PRVB and OCGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
June 21, 2021 | finance.yahoo.com

FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
June 18, 2021 | finance.yahoo.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
June 16, 2021 | marketwatch.com

ACAD 2-DAY DEADLINE ALERT: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Now
June 16, 2021 | finance.yahoo.com

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, EBS and PRVB
June 14, 2021 | finance.yahoo.com

ACAD 4-DAY DEADLINE ALERT: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Now Before June 18th Application Deadline
June 14, 2021 | finance.yahoo.com

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ACAD, WISH and SPCE
June 14, 2021 | finance.yahoo.com

ACAD 5-DAY DEADLINE ALERT: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Before June 18th Application Deadline in Securities Class Action
June 13, 2021 | finance.yahoo.com

CLASS ACTION UPDATE for ACAD, EBS and ATER: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
June 13, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACAD
Previous Symbol
CUSIPN/A
CIK1070494
Webwww.acadia-pharm.com
Phone858-558-2871
Employees640
Year FoundedN/A

Sales & Book Value

Annual Sales$441.76 million
Price / Sales9.13
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.94 per share
Price / Book6.39

Profitability

EPS (Most Recent Fiscal Year)($1.79)
Net Income$-281,580,000.00
Net Margins-56.74%
Return on Equity-41.17%
Return on Assets-33.62%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares160,179,000
Market Cap$4.03 billion
Next Earnings Date8/4/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.73 out of 5 stars

Medical Sector

256th out of 2,101 stocks

Pharmaceutical Preparations Industry

122nd out of 831 stocks

3.2 Analyst's Opinion

Consensus Rating
ACADIA Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.32, and is based on 6 buy ratings, 13 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $31.35, ACADIA Pharmaceuticals has a forecasted upside of 24.8% from its current price of $25.13.
Amount of Analyst Coverage
ACADIA Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.2 Community Rank

Outperform Votes
ACADIA Pharmaceuticals has received 803 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ACADIA Pharmaceuticals has received 454 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ACADIA Pharmaceuticals has received 63.88% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote “Outperform” if you believe ACAD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ACADIA Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ACADIA Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $287,995.00 in company stock.
Percentage Held by Insiders
Only 28.50% of the stock of ACADIA Pharmaceuticals is held by insiders.
Percentage Held by Institutions
90.19% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for ACADIA Pharmaceuticals are expected to grow in the coming year, from ($1.26) to ($0.83) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ACADIA Pharmaceuticals is -15.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ACADIA Pharmaceuticals is -15.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ACADIA Pharmaceuticals has a P/B Ratio of 6.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

Is ACADIA Pharmaceuticals a buy right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 13 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ACADIA Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View analyst ratings for ACADIA Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than ACADIA Pharmaceuticals?

Wall Street analysts have given ACADIA Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ACADIA Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a decline in short interest in May. As of May 28th, there was short interest totaling 5,800,000 shares, a decline of 20.0% from the May 13th total of 7,250,000 shares. Based on an average trading volume of 2,220,000 shares, the short-interest ratio is currently 2.6 days. Currently, 3.6% of the company's shares are sold short.
View ACADIA Pharmaceuticals' Short Interest.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for ACADIA Pharmaceuticals.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its earnings results on Tuesday, May, 4th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.53) by $0.11. The biopharmaceutical company earned $106.55 million during the quarter, compared to the consensus estimate of $112.91 million. ACADIA Pharmaceuticals had a negative net margin of 56.74% and a negative trailing twelve-month return on equity of 41.17%.
View ACADIA Pharmaceuticals' earnings history.

How has ACADIA Pharmaceuticals' stock price been impacted by COVID-19?

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACAD stock has decreased by 31.7% and is now trading at $25.17.
View which stocks have been most impacted by COVID-19.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $510 million-$550 million, compared to the consensus revenue estimate of $535.93 million.

What price target have analysts set for ACAD?

19 brokerages have issued 1-year price objectives for ACADIA Pharmaceuticals' shares. Their forecasts range from $18.00 to $57.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $31.35 in the next twelve months. This suggests a possible upside of 24.6% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the following people:

Mr. Stephen R. Davis, CEO & Director (Age 60, Pay $1.23M)
Dr. Srdjan R. Stankovic, Pres (Age 64, Pay $1.12M)
Ms. Elena H. Ridloff C.F.A., CFA, Exec. VP & CFO (Age 41, Pay $646.54k)
Mr. Austin D. Kim, Exec. VP, Gen. Counsel & Sec. (Age 57, Pay $626.76k)
Mr. James K. Kihara, VP, Corp. Controller & Principal Accounting Officer (Age 41)
Mr. Bob Mischler, Sr. VP of Strategy & Technology Operations
Mr. Mark C. Johnson, VP of Investor Relations
Ms. Stephanie Fagan, Sr. VP of Corp. Affairs & Chief Communications Officer
Ms. Charmaine Lykins, Sr. VP of Global Product Planning & Chief Marketing Officer
Dr. Mary Ellen Turner, Sr. VP of Pharmacovigilance & Corp. Safety Officer

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among ACADIA Pharmaceuticals' employees.

Who are some of ACADIA Pharmaceuticals' key competitors?

Some companies that are related to ACADIA Pharmaceuticals include Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Zai Lab (ZLAB), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), CureVac (CVAC), Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX) and United Therapeutics (UTHR).
View all of ACAD's competitors.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (26.16%), Price T Rowe Associates Inc. MD (5.22%), BlackRock Inc. (4.62%), Janus Henderson Group PLC (3.36%), Fred Alger Management LLC (1.74%) and Ameriprise Financial Inc. (1.52%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals.

Which institutional investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Great Point Partners LLC, PFM Health Sciences LP, UBS Asset Management Americas Inc., Allianz Asset Management GmbH, Polar Capital Holdings Plc, Ensign Peak Advisors Inc, and Cubist Systematic Strategies LLC. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, Michael J Yang, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Ameriprise Financial Inc., Federated Hermes Inc., Voloridge Investment Management LLC, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Fred Alger Management LLC, and Woodline Partners LP.
View insider buying and selling activity for ACADIA Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $25.17.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals has a market capitalization of $4.03 billion and generates $441.76 million in revenue each year. The biopharmaceutical company earns $-281,580,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals employs 640 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

Where are ACADIA Pharmaceuticals' headquarters?

ACADIA Pharmaceuticals is headquartered at 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]

This page was last updated on 6/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here